Implants for sculpting, augmenting or correcting facial features such as the chin

Patent metadata

Field	Value
Publication number	US-12324868-B2
Application number	US-202217943075-A
Country	US
Kind code	B2
Filing date	Sep 12, 2022
Priority date	Feb 13, 2015
Publication date	Jun 10, 2025
Grant date	Jun 10, 2025

Abstract

An injectable device, comprising a hyaluronic acid-based composition, useful for long lasting facial sculpting and correction of facial features, for example, for augmenting and shaping the profile, including for example, the chin, jawline or the nose, in a human being is provided. Methods of treatment are also provided.

First claim

What is claimed is:

1. A composition comprising a crosslinked hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether;
wherein the hyaluronic acid used for crosslinking comprises a mixture of:
(i) at least 50% by weight, based on the total weight of the hyaluronic acid, of a low molecular weight hyaluronic acid having a weight average molecular weight of between about 750,000 Da and about 1.0 MDa, and
(ii) a high molecular weight hyaluronic acid having a weight average molecular weight of between about 2.0 MDa and about 4.0 MDa; and

wherein the composition:
(a) has a hyaluronic acid concentration greater than 20 mg/g to about 30 mg/g,
(b) has an elastic modulus between about 500 Pa and about 900 Pa at 5 Hz,
(c) has a cohesivity between about 60 gmf and about 200 gmf,
(d) has an extrusion force between about 4N and about 15N at 13 mm/min using a 1 mL COC syringe and a 27G×13 mm needle, and
(e) is implantable subdermally or supraperiostially into the chin area, jawline, or nose of a patient.

2. The composition of claim 1 , wherein the low molecular weight hyaluronic acid has a weight average molecular weight of between about 750,000 Da and about 0.99 MDa.

3. The composition of claim 1 , wherein the high molecular weight hyaluronic acid has a weight average molecular weight of between about 2.4 MDa and about 3.6 MDa.

4. The composition of claim 1 , wherein the hyaluronic acid concentration is about 22 mg/g to about 28 mg/g.

5. The composition of claim 1 , wherein the hyaluronic acid concentration is about 24 mg/g to about 26 mg/g.

6. The composition of claim 1 , wherein the hyaluronic acid concentration is about 25 mg/g.

7. The composition of claim 1 , wherein the crosslinked hyaluronic acid has a degree of crosslinking of between about 4% and about 10%.

8. The composition of claim 1 , wherein the hyaluronic acid used for crosslinking comprises a mixture of: (i) at least 70% by weight of the low molecular weight hyaluronic acid, and (ii) the high molecular weight hyaluronic acid.

9. The composition of claim 1 , wherein the hyaluronic acid used for crosslinking comprises a mixture of (i) about 90% by weight of low molecular weight hyaluronic acid, based on the total weight of the hyaluronic acid, and (ii) about 10% by weight of the high molecular weight hyaluronic acid, based on the total weight of the hyaluronic acid.

10. The composition of claim 1 , wherein the cohesivity is between about 60 gmf and about 100 gmf.

11. The composition of claim 1 , wherein the extrusion force is between about 7N and about 12N at 13 mm/min using a 1 mL COC syringe and a 27G×13 mm needle.

12. The composition of claim 1 , wherein the composition further comprises an anesthetic agent.

13. The composition of claim 12 , wherein the anesthetic agent is lidocaine hydrochloride.

14. The composition of claim 1 , wherein the composition further comprises uncrosslinked hyaluronic acid.

15. A composition, implantable subdermally or supraperiostially into the chin area, jawline, or nose of a patient, the composition comprising a crosslinked hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether;
wherein the crosslinked hyaluronic acid has a degree of crosslinking of between about 4% and about 10%;
wherein the hyaluronic acid used for crosslinking comprises a mixture of:
(i) at least 70% by weight, based on the total weight of the hyaluronic acid, of a low molecular weight hyaluronic acid having a weight average molecular weight of between about 750,000 Da and about 0.99 MDa, and
(ii) a high molecular weight hyaluronic acid having a weight average molecular weight of between about 2.4 MDa and about 3.6 MDa; and

wherein the composition has:
(a) a hyaluronic acid concentration of about 22.5 mg/g to about 27.5 mg/g,
(b) an elastic modulus between about 500 Pa and about 900 Pa at 5 Hz,
(b) a cohesivity between about 60 gmf and about 200 gmf, and
(e) an extrusion force between about 4N and about 12N at 13 mm/min using a 1 mL COC syringe and a 27G×13 mm needle.

16. A method of augmenting, correcting, restoring, or creating volume in a chin of a subject in need thereof, the method comprising injecting the composition of claim 15 into the chin of the subject.

17. A method of augmenting, correcting, restoring, or creating volume in the jawline or nose of a subject in need thereof, the method comprising injecting the composition of claim 15 into the jawline or nose of the subject.

18. A method of augmenting, correcting, restoring, or creating volume in a chin of a subject in need thereof, the method comprising injecting the composition of claim 1 into the chin of the subject.

19. A method of augmenting, correcting, restoring, or creating volume in the jawline of a subject in need thereof, the method comprising injecting the composition of claim 1 into the jawline of the subject.

20. A method of augmenting, correcting, restoring, or creating volume in nose of a subject in need thereof, the method comprising injecting the composition of claim 1 into the nose of the subject.

Assignees

• Allergan Ind Sas

Inventors

• Roca Martinez Jean Xavier
• Ayglon Aurore

Classifications

• C08B37/0072

  Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates · CPC title

• A61M5/329

  characterised by features of the needle shaft · CPC title

• A61L2300/402

  Anaestetics, analgesics, e.g. lidocaine · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L27/12

  Phosphorus-containing materials, e.g. apatite · CPC title